Journal of the American Society of Hypertension
Volume 1, Issue 2 , Pages 150-160 , March 2007

Inhibitory effects of PPAR-γ on endothelin-1-induced inflammatory pathways in vascular smooth muscle cells from normotensive and hypertensive rats

  • Augusto C. Montezano, PhD

      Affiliations

    • Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
    • ,
  • Farhad Amiri, PhD

      Affiliations

    • Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada
    • ,
  • Rita C. Tostes, PhD

      Affiliations

    • Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
    • ,
  • Rhian M. Touyz, MD, PhD

      Affiliations

    • Kidney Research Centre, Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada
    • ,
  • Ernesto L. Schiffrin, MD, PhD, FRCPC

      Affiliations

    • Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada
    • Corresponding Author InformationCorresponding author: Ernesto L. Schiffrin, MD, PhD, FRCPC, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Côte Ste-Catherine Road, B-127, Montreal, Quebec, Canada H3T 1E2. Tel: 514-340-7538; fax: 514-340-7539.

Received 1 December 2006 ,Accepted 18 January 2007.

References 

  1. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension. 2000;36:312–318
  2. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation. 2004;110:2233–2240
  3. Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol. 2005;43:19–29
  4. Neves MF, Amiri F, Virdis A, Diep QN, Schiffrin EL. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can J Physiol Pharmacol. 2005;83:999–1006
  5. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol. 2005;25:2106–2113
  6. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens. 2001;14:S83–S89
  7. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066–1071
  8. Cristiani C, Volpi D, Landonio A, Bertolero F. Endothelin-1-selective binding sites are downregulated by transforming growth factor-beta and upregulated by basic fibroblast growth factor in a vascular smooth muscle-derived cell line. J Cardiovasc Pharmacol. 1994;23:988–994
  9. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ETA receptors. Hypertension. 2002;39:679–684
  10. Sharifi AM, He G, Touyz RM, Schiffrin EL. Vascular endothelin-1 expression and effect of an endothelin ETA antagonist on structure and function of small arteries from stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1998;31(suppl 1):S309–S312
  11. Okada M, Kobayashi M, Maruyama H, Takahashi R, Ikemoto F, Yano M, et al. Effects of a selective endothelin A-receptor antagonist, BQ-123, in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1995;22:763–768
  12. Chillon JM, Heistad DD, Baumbach GL. Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats. Hypertension. 1996;27:794–798
  13. Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL. Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol. 2003;23:45–51
  14. Martin-Nizard F, Furman C, Delerive P, Kandoussi A, Fruchart JC, Staels B, et al. Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Pharmacol. 2002;40:822–831
  15. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168–1178
  16. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation. 2000;101:1311–1318
  17. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 2001;169:453–459
  18. Benkirane K, Amiri F, Diep QN, El Mabrouk M, Schiffrin EL. PPAR-γ inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol. 2006;290:H390–H397
  19. Diep QN, Schiffrin EL. Increased expression of peroxisome proliferator-activated receptor-α and -γ in blood vessels of spontaneously hypertensive rats. Hypertension. 2001;38:249–254
  20. Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G, et al. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κB. J Biol Chem. 2000;275:32681–32687
  21. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res. 1999;85:394–402
  22. Goetze S, Xi XP, Graf K, Fleck E, Hsueh WA, Law RE. Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett. 1999;452:277–282
  23. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation. 2002;105:2296–2302
  24. Schiffrin EL, Lariviere R, Touyz RM. ETA and ETB receptors on vascular smooth muscle cells from mesenteric vessels of spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl. 1995;22:S193–S194
  25. Virdis A, Neves MF, Amiri F, Touyz RM, Schiffrin EL. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens. 2004;22:535–542
  26. Touyz RM, Deng LY, He G, Wu XH, Schiffrin EL. Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases. J Hypertens. 1999;17:907–916
  27. Mangelus M, Galron R, Naor Z, Sokolovsky M. Involvement of nuclear factor-κB in endothelin-A-receptor-induced proliferation and inhibition of apoptosis. Cell Mol Neurobiol. 2001;21:657–674
  28. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell. 1996;87:13–20
  29. Parry GC, Mackman N. A set of inducible genes expressed by activated human monocytic and endothelial cells contain κB-like sites that specifically bind c-Rel-p65 heterodimers. J Biol Chem. 1994;269:20823–20825
  30. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IκB kinase. Cell. 1997;90:373–383
  31. Johnson DR, Douglas I, Jahnke A, Ghosh S, Pober JS. A sustained reduction in IκB-β may contribute to persistent NF-κB activation in human endothelial cells. J Biol Chem. 1996;271:16317–16322
  32. Mercurio F, Manning AM. Multiple signals converging on NF-κB. Curr Opin Cell Biol. 1999;11:226–232
  33. Madrid LV, Mayo MW, Reuther JY, Baldwin ASJ. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-κB through utilization of the IκB kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem. 2001;276:18934–18940
  34. Yamawaki H, Lehoux S, Berk BC. Chronic physiological shear stress inhibits tumor necrosis factor-induced proinflammatory responses in rabbit aorta perfused ex vivo. Circulation. 2003;108:1619–1625
  35. Shibuya T, Takei Y, Hirose M, Ikejima K, Enomoto N, Maruyama A, et al. A double-strand decoy DNA oligomer for NF-κB inhibits TNFα-induced ICAM-1 expression in sinusoidal endothelial cells. Biochem Biophys Res Commun. 2002;298:10–16
  36. Wu D, Marko M, Claycombe K, Paulson KE, Meydani SN. Ceramide-induced and age-associated increase in macrophage COX-2 expression is mediated through up-regulation of NF-κB activity. J Biol Chem. 2003;278:10983–10992
  37. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens. 2006;15:152–158
  38. Sironi L, Gianazza E, Gelosa P, Guerrini U, Nobili E, Gianella A, et al. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by anti-inflammatory effects. Arterioscler Thromb Vasc Biol. 2005;25:598–603
  39. Li L, Chu Y, Fink GD, Engelhardt JF, Heistad DD, Chen AF. Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension. Hypertension. 2003;42:997–1003
  40. Russo D, Minutolo R, Clienti C, De NL, Iodice C, Savino FA, et al. Endothelin-1 released by vascular smooth muscle cells enhances vascular responsiveness of rat mesenteric arterial bed exposed to high perfusion flow. Am J Hypertens. 1999;12:1119–1123
  41. Sutherland AJ, Nataatmadja MI, Walker PJ, Cuttle L, Garlick RB, West MJ. Vascular remodeling in the internal mammary artery graft and association with in situ endothelin-1 and receptor expression. Circulation. 2006;113:1180–1188
  42. Battistini B, Steil AA, Jancar S, Sirois P. Roles of endothelins and their receptors in immune complex-induced/polymorphonuclear-mediated lung injury (reversed passive arthus reaction) in CD-1 mice. Pulm Pharmacol Ther. 1998;11:165–172
  43. Todd KE, Lewis MP, Gloor B, Lane JS, Ashley SW, Reber HA. An ETa/ETb endothelin antagonist ameliorates systemic inflammation in a murine model of acute hemorrhagic pancreatitis. Surgery. 1997;122:443–449
  44. Wilson SH, Simari RD, Lerman A. The effect of endothelin-1 on nuclear factor kappa B in macrophages. Biochem Biophys Res Commun. 2001;286:968–972
  45. Bauer B, Hartz AM, Miller DS. TNF-α and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol. 2006;In press
  46. Satoh H, Tsukamoto K, Hashimoto Y, Hashimoto N, Togo M, Hara M, et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARγ on vascular endothelial function. Biochem Biophys Res Commun. 1999;254:757–763
  47. Benkirane K, Viel EC, Amiri F, Schiffrin EL. Peroxisome proliferator-activated receptor γ regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension. 2006;47:102–108
  48. Gao DF, Niu XL, Hao GH, Peng N, Wei J, Ning N, et al. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells: role of PPAR-γ in vascular fibrosis. Biochem Pharmacol. 2006;73:185–197
  49. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science. 1996;274:2100–2103
  50. Camp HS, Tafuri SR, Leff T. c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-γ1 and negatively regulates its transcriptional activity. Endocrinology. 1999;140:392–397
  51. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888–1904

 This work was supported by Grants 37917 (to Dr. Schiffrin) and 44018 (to Dr. Touyz), and by a group grant to the Multidisciplinary Research Group on Hypertension, all from the Canadian Institutes of Health Research (CIHR). Drs. Touyz and Schiffrin are recipients of Canada Research Chairs. Drs. Montezano and Tostes were supported by CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior), CNPq (Conselho Nacional De Desenvolvimento Científico e Tecnológico) and FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo; 01/13642-3), Brazil.Conflict of interest: none.

PII: S1933-1711(07)00017-4

doi: 10.1016/j.jash.2007.01.005

Journal of the American Society of Hypertension
Volume 1, Issue 2 , Pages 150-160 , March 2007

Article Tools

* Image Usage & Resolution